Technical Analysis for CLVS - Clovis Oncology, Inc.

Grade Last Price % Change Price Change
F 5.09 4.30% 0.21
CLVS closed up 4.3 percent on Wednesday, July 28, 2021, on 46 percent of normal volume.
Earnings due: Aug 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical CLVS trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Stochastic Buy Signal Bullish 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish 4.30%
Outside Day Range Expansion 4.30%
Lower Bollinger Band Touch Weakness 4.30%
Oversold Stochastic Weakness 4.30%
Down 3 Days in a Row Weakness 6.93%
Oversold Stochastic Weakness 6.93%
Stochastic Reached Oversold Weakness 4.73%
Older End-of-Day Signals for CLVS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 14 hours ago
Rose Above 10 DMA about 15 hours ago
Possible NR7 about 15 hours ago
10 DMA Resistance about 16 hours ago
60 Minute Opening Range Breakout about 17 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Clovis Oncology, Inc. Description

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Disease Chemical Compounds Drug Discovery Organic Compounds Gastrointestinal Breast Cancer Treatment Of Breast Cancer Non Small Cell Lung Cancer Small Cell Lung Cancer Adp Epidermal Growth Factor Receptor Lung Cancer Treatment Of Non Small Cell Lung Cancer Gastrointestinal Stromal Tumor Lactams Indoles Foundation Medicine Heterocyclic Compounds

Is CLVS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 11.1
52 Week Low 4.08
Average Volume 6,290,816
200-Day Moving Average 5.80
50-Day Moving Average 5.50
20-Day Moving Average 5.26
10-Day Moving Average 5.02
Average True Range 0.29
ADX 12.08
+DI 22.11
-DI 26.81
Chandelier Exit (Long, 3 ATRs) 5.78
Chandelier Exit (Short, 3 ATRs) 5.51
Upper Bollinger Bands 5.84
Lower Bollinger Band 4.67
Percent B (%b) 0.36
BandWidth 22.20
MACD Line -0.21
MACD Signal Line -0.19
MACD Histogram -0.0248
Fundamentals Value
Market Cap 526.47 Million
Num Shares 103 Million
EPS -7.50
Price-to-Earnings (P/E) Ratio -0.68
Price-to-Sales 2.19
Price-to-Book 0.00
PEG Ratio 0.13
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.47
Resistance 3 (R3) 5.43 5.27 5.41
Resistance 2 (R2) 5.27 5.17 5.29 5.39
Resistance 1 (R1) 5.18 5.11 5.22 5.22 5.37
Pivot Point 5.01 5.01 5.03 5.03 5.01
Support 1 (S1) 4.92 4.91 4.97 4.96 4.81
Support 2 (S2) 4.76 4.85 4.78 4.79
Support 3 (S3) 4.67 4.76 4.77
Support 4 (S4) 4.71